These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9196222)

  • 1. Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli.
    O'Shaughnessy EM; Fahle GA; Witebsky FG
    J Clin Microbiol; 1997 Jul; 35(7):1902-3. PubMed ID: 9196222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.
    Oliver A; Pérez-Vázquez M; Martínez-Ferrer M; Baquero F; De Rafael L; Cantón R
    Antimicrob Agents Chemother; 1999 Apr; 43(4):862-7. PubMed ID: 10103192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.
    Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.
    Fuchs PC; Barry AL; Pfaller MA; Hardy DJ; McLaughlin JC; Gerlach EH
    Diagn Microbiol Infect Dis; 1993; 17(2):171-5. PubMed ID: 8243040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing breakpoints for amoxicillin/clavulanate and ampicillin/sulbactam for rapid antimicrobial susceptibility testing directly from positive blood culture bottles.
    König E; Iser J; Zechner-Sammer T; Friedl H; Krause R; Valentin T; Leitner E; Steinmetz I; Zollner-Schwetz I
    J Med Microbiol; 2023 Mar; 72(3):. PubMed ID: 36951904
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae].
    Cisterna R; Fresnadillo MJ; García-Rodríguez JA; Gobernado M; Martín R; Perea E; Picazo J
    Rev Esp Quimioter; 1998 Sep; 11(3):245-50. PubMed ID: 9795311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
    Gisby J; Beale AS
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
    Simpson I; Durodie J; Knott S; Shea B; Wilson J; Machka K
    J Clin Microbiol; 1998 May; 36(5):1361-5. PubMed ID: 9574706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactams susceptibility testing of penicillin-resistant, ampicillin-susceptible Enterococcus faecalis isolates: a comparative assessment of Etest and disk diffusion methods against broth dilution.
    Conceição N; Rodrigues WF; de Oliveira KLP; da Silva LEP; de Souza LRC; da de Cunha Hueb Barata Oliveira C; de Oliveira AG
    Ann Clin Microbiol Antimicrob; 2020 Sep; 19(1):43. PubMed ID: 32943051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretive criteria for susceptibilities of Haemophilus influenzae to ampicillin, amoxicillin, and amoxicillin-clavulanic acid.
    Fuchs PC; Barry AL
    J Clin Microbiol; 1994 Nov; 32(11):2846-50. PubMed ID: 7852584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli.
    Leverstein-van Hall MA; Waar K; Muilwijk J; Cohen Stuart J;
    J Antimicrob Chemother; 2013 Nov; 68(11):2636-40. PubMed ID: 23766488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Shungu DL; Ponticas S; Gill CJ
    Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ampicillin susceptibilities of vaginal and placental isolates of group B streptococcus and Escherichia coli obtained between 1992 and 1994.
    Meyn LA; Hillier SL
    Antimicrob Agents Chemother; 1997 May; 41(5):1173-4. PubMed ID: 9145894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.